Clinical Trials DEA Epilepsy Research and Development 
Veriheal
APRIL 11, 2022
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
MedicalJane
JUNE 29, 2018
The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Prior to this week, the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
AUGUST 8, 2020
Researchers believe cannabis contains over 100 unique chemical compounds! Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential.
Veriheal
AUGUST 31, 2020
We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.
Cannabis Law Report
JULY 12, 2019
By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC.
Expert insights. Personalized for you.
104 
Let's personalize your content